| scholarly article | Q13442814 |
| P2093 | author name string | Gun Jörneskog | |
| Thomas Kahan | |||
| N Håkan Wallén | |||
| Mikael Ekholm | |||
| Jonas Brinck | |||
| P2860 | cites work | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Fat as an endocrine organ: relationship to the metabolic syndrome. | Q30352208 | ||
| Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo | Q31404999 | ||
| Syncope with cardiac arrest in a 30-year-old woman | Q33148643 | ||
| AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology | Q33751628 | ||
| Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. | Q33898507 | ||
| Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture | Q33947317 | ||
| Vascular inflammation and the renin-angiotensin system | Q33960784 | ||
| Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study | Q34470547 | ||
| Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia | Q34506656 | ||
| Angiotensin and vascular fibrinolytic balance | Q34515014 | ||
| Interactions of intercellular adhesion molecule-1 with fibrinogen | Q34635635 | ||
| Familial hypercholesterolemia from children to adults | Q35090318 | ||
| Leukocyte count and coronary heart disease: implications for risk assessment | Q35948300 | ||
| Circadian Variation of Fibrinolytic Activity in Blood | Q37054785 | ||
| The pro- and anti-inflammatory properties of the cytokine interleukin-6. | Q37836084 | ||
| Circadian variation and triggers of onset of acute cardiovascular disease | Q38608823 | ||
| Thrombin generation in patients with a first acute myocardial infarction. | Q39807597 | ||
| Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees | Q42062319 | ||
| Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia | Q43218645 | ||
| Peripheral differential leukocyte counts in humans vary with hyperlipidemia, smoking, and body mass index | Q43598208 | ||
| Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity | Q43633680 | ||
| Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells | Q44000911 | ||
| Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension | Q44083513 | ||
| Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects | Q44786125 | ||
| Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia | Q46250799 | ||
| Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome | Q46876508 | ||
| Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. | Q50776752 | ||
| High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. | Q51353756 | ||
| Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. | Q51574692 | ||
| Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. | Q51838839 | ||
| Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
| Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. | Q52846195 | ||
| Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. | Q53891281 | ||
| C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease | Q57605886 | ||
| P433 | issue | 2 | |
| P921 | main subject | hypercholesterolemia | Q762713 |
| P304 | page(s) | 328-338 | |
| P577 | publication date | 2015-04-22 | |
| P1433 | published in | Journal of the Renin-Angiotensin-Aldosterone System | Q6296180 |
| P1476 | title | Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion. | |
| P478 | volume | 16 |
| Q94597167 | Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19? | cites work | P2860 |
Search more.